Solid Biosciences (SLDB) Stock Price

Solid Biosciences develops gene transfer therapies for Duchenne muscular dystrophy, focusing on SGT-001 and SGT-003, which address the genetic cause by delivering synthetic transgenes producing dystrophin-like proteins. The company also works on AVB-202 for Friedreichs ataxia and AVB-401 for BAG3-mediated dilated cardiomyopathy, alongside platform technologies like novel capsid libraries and dual gene expression for packaging multiple transgenes. Its programs target neuromuscular and cardiac conditions, with SGT-003 specifically designed for muscle-specific expression including cardiac and respiratory muscles. The company's revenue streams come from developing these therapies for clinical trials and potential future commercialization. Solid Biosciences' primary customers are patients with Duchenne muscular dystrophy, Friedreichs ataxia, and BAG3-mediated dilated cardiomyopathy, seeking treatments for these rare neuromuscular and cardiac conditions. The company's development programs are focused on creating therapies that address the underlying genetic causes, aiming to provide long-term solutions rather than symptomatic relief. Its platform technologies, such as dual gene expression, support the creation of more efficient gene transfer vectors for future therapies. The company's key products include SGT-001, SGT-003, AVB-202, and AVB-401, each targeting specific genetic disorders. SGT-003 is designed to produce dystrophin-like protein exclusively in muscles, including cardiac and respiratory muscles, while AVB-202 and AVB-401 target Friedreichs ataxia and dilated cardiomyopathy, respectively. Solid Biosciences generates revenue through the development and potential commercialization of these gene transfer candidates, with a focus on rare diseases where current treatments are limited.